Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38

1.

Correction: Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013).

An HJ, Lee B, Kim DH, Lee EK, Chung KW, Park MH, Jeong HO, Kim SM, Moon KM, Kim YR, Kim SJ, Yun HY, Chun P, Yu BP, Moon HR, Chung HY.

Oncotarget. 2017 Jul 4;8(27):45030. doi: 10.18632/oncotarget.18922. No abstract available.

2.

Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging.

Kim SM, Lee B, An HJ, Kim DH, Park KC, Noh SG, Chung KW, Lee EK, Kim KM, Kim DH, Kim SJ, Chun P, Lee HJ, Moon HR, Chung HY.

Oncotarget. 2017 Jul 11;8(28):46273-46285. doi: 10.18632/oncotarget.17695.

3.

Design, synthesis, and antimelanogenic effects of (2-substituted phenyl-1,3-dithiolan-4-yl)methanol derivatives.

Kim DH, Kim SJ, Ullah S, Yun HY, Chun P, Moon HR.

Drug Des Devel Ther. 2017 Mar 16;11:827-836. doi: 10.2147/DDDT.S131538. eCollection 2017.

4.

Physiological characterization of a novel PPAR pan agonist, 2-(4-(5,6-methylenedioxybenzo[d]thiazol-2-yl)-2-methylphenoxy)-2-methylpropanoic acid (MHY2013).

An HJ, Lee B, Kim DH, Lee EK, Chung KW, Park MH, Jeong HO, Kim SM, Moon KM, Kim YR, Kim SJ, Yun HY, Chun P, Yu BP, Moon HR, Chung HY.

Oncotarget. 2017 Mar 7;8(10):16912-16924. doi: 10.18632/oncotarget.14818. Erratum in: Oncotarget. 2017 Jul 4;8(27):45030.

5.

Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding.

Park EY, Woo Y, Kim SJ, Kim DH, Lee EK, De U, Kim KS, Lee J, Jung JH, Ha KT, Choi WS, Kim IS, Lee BM, Yoon S, Moon HR, Kim HS.

Int J Biol Sci. 2016 Dec 6;12(12):1555-1567. eCollection 2016.

6.

Increased therapeutic efficacy of a newly synthesized tyrosinase inhibitor by solid lipid nanoparticles in the topical treatment of hyperpigmentation.

Al-Amin M, Cao J, Naeem M, Banna H, Kim MS, Jung Y, Chung HY, Moon HR, Yoo JW.

Drug Des Devel Ther. 2016 Dec 2;10:3947-3957. eCollection 2016.

7.

(Z)-5-(2,4-Dihydroxybenzylidene)thiazolidine-2,4-dione Prevents UVB-Induced Melanogenesis and Wrinkle Formation through Suppressing Oxidative Stress in HRM-2 Hairless Mice.

Lee B, Moon KM, Kim SJ, Kim SH, Kim DH, An HJ, Jeong JW, Kim YR, Son S, Kim MJ, Chung KW, Lee EK, Chun P, Ha YM, Kim MS, Mo SH, Moon HR, Chung HY.

Oxid Med Cell Longev. 2016;2016:2761463. doi: 10.1155/2016/2761463. Epub 2016 May 8.

8.
9.

Design, synthesis, and anti-melanogenic effects of (E)-2-benzoyl-3-(substituted phenyl)acrylonitriles.

Yun HY, Kim DH, Son S, Ullah S, Kim SJ, Kim YJ, Yoo JW, Jung Y, Chun P, Moon HR.

Drug Des Devel Ther. 2015 Aug 4;9:4259-68. doi: 10.2147/DDDT.S89976. eCollection 2015.

10.

Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.

Ha ES, Kim JS, Baek IH, Yoo JW, Jung Y, Moon HR, Kim MS.

Drug Des Devel Ther. 2015 Aug 4;9:4269-77. doi: 10.2147/DDDT.S90706. eCollection 2015.

11.

A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis.

Choo J, Lee Y, Yan XJ, Noh TH, Kim SJ, Son S, Pothoulakis C, Moon HR, Jung JH, Im E.

J Biol Chem. 2015 Oct 16;290(42):25609-19. doi: 10.1074/jbc.M115.673046. Epub 2015 Sep 4.

12.

A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1.

De U, Kundu S, Patra N, Ahn MY, Ahn JH, Son JY, Yoon JH, Moon HR, Lee BM, Kim HS.

Biomol Ther (Seoul). 2015 Sep;23(5):434-41. doi: 10.4062/biomolther.2015.026. Epub 2015 Sep 1.

13.

Evaluation of glycine-bearing celecoxib derivatives as a colon-specific mutual prodrug acting on nuclear factor-κB, an anti-inflammatory target.

Lee S, Lee Y, Kim W, Nam J, Jeong S, Yoo JW, Kim MS, Moon HR, Jung Y.

Drug Des Devel Ther. 2015 Aug 7;9:4227-37. doi: 10.2147/DDDT.S88543. eCollection 2015.

14.

Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy.

Naeem M, Choi M, Cao J, Lee Y, Ikram M, Yoon S, Lee J, Moon HR, Kim MS, Jung Y, Yoo JW.

Drug Des Devel Ther. 2015 Jul 21;9:3789-99. doi: 10.2147/DDDT.S88672. eCollection 2015.

15.

Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles.

Naeem M, Cao J, Choi M, Kim WS, Moon HR, Lee BL, Kim MS, Jung Y, Yoo JW.

Int J Nanomedicine. 2015 Jul 16;10:4565-80. doi: 10.2147/IJN.S87816. eCollection 2015.

16.

Treatment with the pinhole technique using erbium-doped yttrium aluminium garnet laser for a café au lait macule and carbon dioxide laser for facial telangiectasia.

Chung BY, Han SS, Moon HR, Lee MW, Chang SE.

Ann Dermatol. 2014 Oct;26(5):657-9. doi: 10.5021/ad.2014.26.5.657. Epub 2014 Sep 26. No abstract available.

17.

Recent chemotherapy reduces the maximum-standardized uptake value of 18F-fluoro-deoxyglucose positron emission tomography in colorectal cancer.

Lee M, Yeum TS, Kim JW, Oh S, Lee SA, Moon HR, Choi YH, Han YM, Choi JM, Jang DK.

Gut Liver. 2014 May;8(3):254-64. doi: 10.5009/gnl.2014.8.3.254.

18.

Grover's Disease in a Liver Transplant Patient.

Moon HR, Lee JH, Rhee DY, Won CH, Chang SE, Lee MW, Choi JH, Moon KC.

Ann Dermatol. 2014 Feb;26(1):117-8. doi: 10.5021/ad.2014.26.1.117. Epub 2014 Feb 17. No abstract available.

19.

Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice.

Park MH, Park JY, Lee HJ, Kim DH, Park D, Jeong HO, Park CH, Chun P, Moon HR, Chung HY.

PLoS One. 2013 Nov 14;8(11):e78815. doi: 10.1371/journal.pone.0078815. eCollection 2013.

20.

The novel PPAR α/γ dual agonist MHY 966 modulates UVB-induced skin inflammation by inhibiting NF-κB activity.

Park MH, Park JY, Lee HJ, Kim DH, Chung KW, Park D, Jeong HO, Kim HR, Park CH, Kim SR, Chun P, Byun Y, Moon HR, Chung HY.

PLoS One. 2013 Oct 9;8(10):e76820. doi: 10.1371/journal.pone.0076820. eCollection 2013.

Supplemental Content

Loading ...
Support Center